CLINICAL PROTOCOL AND DATA MANAGEMENT (Core-176) ABSTRACT Overview: The Clinical Protocol and Data Management (CPDM) provides central management and oversight functions for coordinating, facilitating and reporting on clinical and population sciences trials across the UCCC consortium which serve our catchment area of the State of Colorado. The CPDM is led by Thomas Flaig MD, Associate Director for Clinical Research and supported by Colleen Kellackey RN, Consortium Clinical Research Director. The UCCC Data and Safety Monitoring Plan (DSMP) was approved by the NCI in October, 2014. The Data Safety and Monitoring Committee (DSMC) provides a robust structure for auditing clinical trials across the consortium. DSMC's oversight is prioritized for high-risk Phase I and Phase II protocols. Accomplishments: Since 2011, the CPDM substantially improved clinical research support as follows: 1) CPDM led an institutional- wide effort to select and implement the OnCore commercial clinical trial management system (CTMS) integrated with the UCD clinical data repository (Health Data Compass). OnCore was activated July 2015; 2) CPDM leadership implemented an acuity tool to right-size the clinical research staff for the adult Cancer Clinical Trials Office (CCTO); 3) CPDM increased its support for institutional trials by adding staff; and the 4) the DSMC auditing capacity was increased by 2 auditors. Quality Control and Training: An education coordinator position was added to the CPDM. In addition to outlining and coordinating training and orientation for data managers, nurses and new faculty, the coordinator works closely with the DSMC to review trends from internal and external audits. Based on these findings, the coordinator works with the CPDM leadership to develop focused educational outreach to clinical investigators and recommends policy updates to improve the quality and compliance of clinical research. Trials and Catchment Area Demographics: The CPDM oversees an annual average of 382 clinical research studies. In FY2015 1,499 patients were accrued to intervention studies and 706 were accrued to intervention-treatment studies representing 18% of the analytic cases reported by UCH, CHCO and the VA. Patients accrued to clinical trials come from 61 of 64 Colorado counties. Based on data from 2015: 1) Although approximately half the cancer population is female, 58% of the accrued patients were female, representing a substantial increase from 2012 (49%) and 2) 3% and 5% of patient accruals were African American and Hispanic, respectively. UCCC continues to enroll women and African Americans in rates that are consistent with the cancer incidence in these specific populations and has a plan to increase Hispanic enrollment to at least 10%, consistent with the cancer incidence in the population. Taken together, these data demonstrate substantial progress in the CPDM and further demonstrate the UCCC's commitment and success in providing safe and equitable clinical investigative opportunities to Colorado's cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-30
Application #
9429058
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-02-01
Budget End
2019-01-31
Support Year
30
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Witt, Davis A; Donson, Andrew M; Amani, Vladimir et al. (2018) Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. Pediatr Blood Cancer 65:e26960
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347
Abraham, Christopher G; Ludwig, Michael P; Andrysik, Zdenek et al. (2018) ?Np63? Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas. Cell Rep 24:3224-3236
Sanchez, Gilson J; Richmond, Phillip A; Bunker, Eric N et al. (2018) Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers. Nucleic Acids Res 46:1756-1776
Noonan, Sinead A; Patil, Tejas; Gao, Dexiang et al. (2018) Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol 13:134-138
Guarnieri, A L; Towers, C G; Drasin, D J et al. (2018) The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L. Oncogene 37:3879-3893
Davies, Kurtis D; Le, Anh T; Sheren, Jamie et al. (2018) Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples. J Thorac Oncol 13:1474-1482
Lyu, Hui; Wang, Shuiliang; Huang, Jingcao et al. (2018) Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer. Cancer Lett 420:97-108
Lee-Sherick, Alisa B; Jacobsen, Kristen M; Henry, Curtis J et al. (2018) MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. JCI Insight 3:
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739

Showing the most recent 10 out of 1634 publications